China Advisory Board Members
Chun-Lin Chen, Ph.D., EMBA – CEO, Shanghai Medicilon Inc.
Dr. Chen is the founder and CEO of Medicilon, which provides high quality preclinical and IND filing services for CFDA and US FDA submissions. He previously served as Director of Pharmaceutical Department at Parker Hughes Institute and as Staff Investigator at Vertex Pharmaceuticals. Currently he serves as Chinese governmental funding reviewer for drug discovery programs and is Adjunct Professor at China Pharmaceutical University.
Yi Feng, MD – Vice President of Medical and Regulatory Affairs, Fountain Medical Development Ltd. (FMD)
Dr. Yi Feng is VP of Medical and Regulatory Affairs at Fountain Medical Development Ltd. He previously served as a senior consultant of drug regulatory affairs at Covington & Burling LLP. Prior to that, he had held several leadership positions during his 17 years’ tenure at the CFDA Center for Drug Evaluation (CDE), including Assistant Director of the CDE and Deputy Director of the Office of the National Major New Drug Discovery Program Implementation. He also worked as an orthopedic surgeon after graduating from Fourth Military Medical University. Dr. Feng has accumulated profound knowledge and expertise in drug evaluation, laws and regulations. He has been involved in making regulatory and scientific decisions for the first approval of many drugs in China in various therapeutic areas. He has led or participated in drafting and formulating many laws, regulations and guidelines in China, and has had in-depth studies in the regulatory systems of Europe, the United States and other countries. He also led the effort to bring the concept of Good Review Practice commonly recognized by international regulatory authorities into China’s evaluation process.
Jin Li, MD – Professor, Tongji University Shanghai East Hospital
Professor Li also serves as the Secretary-General of the Chinese Society of Clinical Oncology. His clinical specialties are comprehensive treatments of gastrointestinal cancer and cancer immunotherapy. He has participated in approximately 100 clinical trials, including more than 10 global trials, for the treatment of various tumor types. He obtained his MD degree from Shanghai Second Military Medical University, completed postdoctoral research at Yale University, and published around 50 papers in prestigious journals.
Xinhui Luan, Ph.D. – General Manager, Beijing Molecular Science and Technology Co Ltd
In addition to his role at Bejing Molecular Science and Technology, Dr. Luan also sits as Professor, and was formally Vice Director, at Academy of Military Medical Sciences (AMMS). He has extensive research experience in natural product chemistry and pharmaceutical chemistry, and expertise in managing institutional research projects. He graduated from Fudan University School of Pharmacy and received his master’s degree and doctorate in medicine from AMMS.
Guozhong Rui, Ph.D. – Director, China Pharmaceutical Technology Transfer Center
Dr. Rui has 26 years of extensive experience in biomedical and pharmaceutical innovation, techno;ogy transfer, commercialization and industrialization. He has facilitated many pharma companies, research institutions, and investment firms to successfully accomplish clinical studies, drug registration, technology evaluation and transfer, as well as financing and acquisition of hundreds of projects. He has been appointed by the Ministry of Science and Technology as a project evaluation expert for the Torch Program and the Technology SME Fund.
Jingsong Wang, MD, PhD – Founder and CEO, Harbour BioMed
Dr. Jingsong Wang is the CEO of Harbour BioMed (HBM). Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women’s Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health. Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.
Chen Yao, MD – Vice Director, Peking University Clinical Research Institute
Professor Yao served as Vice Chairman of the Committee of Evidence-based Medicine at the Chinese Medical Doctor Association. He was formerly with the department of Medical Statistics of PLA General Hospital for 17 years as Professor and Director. He received his MD and MS degrees from the Fourth Military Medical University. As a member on the Expert Committee of New Drug Evaluation of CFDA, he spoke at the 2011 APEC Multi-Regional Clinical Trials Tokyo Workshop, which had China-Japan-South Korea tripartite cooperation as a main topic.
Xiaoping Ye, DPhil, EMBA – Founder, CEO and General Manager, Tigermed Consulting Company
Dr. Ye has over two decades of experience in medical and regulatory affairs. Before founding Tigermed, he worked at global pharmaceutical companies including Xi’an-Janssen, Bristol-Myers Squibb and Shanghai Roche. As Medical and Regulatory Director at Shanghai Roche Pharmaceuticals, he led several international multi-center clinical trials. He graduated from Nanjing Medical College, and received his DPhil degree in Immunology from Oxford University and EMBA from the Guanghua School of Management, Peking University.
Xiong Yu, MSc – Professor & Investigator, China State Institute of Pharmaceutical Industry (CSIPI)
Professor Yu is an investigator at the China National Pharmaceutical Group Corporation and formerly Vice President at CSIPI where he was in charge of business operations and technological innovation. He sits as an Adjunct Professor of Shanghai Jiaotong University and two other universities in China. He has been recognized with five Science and Technology Progress Awards. Currently he is in charge of the Large Platform for Integrative Drug Research and Development at CSIPI.
Suozhong Yuan – Professor, Beijing Shijitan Hospital, Affiliated with Capital Medical University
Professor Suozhong Yuan is Chief Pharmacist and Director of Department of Pharmacy at the Beijing Shijitan Hospital, and Director Emeritus of Department of Clinical Pharmacy, Capital Medical University. Professor Yuan joined the Beijing Shijitan Hospital in 1964 and spent his early career focused on hospital formulation R&D and production, as well as drug product analysis. Since 1980, he has concentrated on rational drug use, clinical evaluation of drugs and clinical management of drug therapies. Professor Yuan has been a council member of the China Pharmaceutical Association (CPA) since 1995 and a member of CPA’s Hospital Pharmacy Committee, of which he was vice chairman during 1995-2010. In 2014 Professor Yuan became the chairman of the Asian Conference on Clinical Pharmacy, having been a chairman-elect in 2012. Due to his long history with and contributions to the CPA, Professor Yuan was selected and appointed as a member of the expert assessment team for the National Work-Related Injuries and Medical Insurance Drug List. Professor Yuan graduated from Nanjing Pharmaceutical College (now China Pharmaceutical University) in 1964. Since then he has published more than 30 research papers, and authored or co-authored more than 20 pharmaceutical textbooks, manuals and dictionaries.
Zhen Zhang, Ph.D. – General Manager, Hubble Kisen Biotech
Dr. Zhang had 11 years’ experience at the Center for Drug Evaluation (CDE) of the China FDA, where he reviewed drugs mainly in the cardiovascular and neuropsychological areas and also in oncology. He has wide expertise in policies, technical requirements and operational methods of drug project initiation, R&D and registration. He received his Ph.D. from the School of Business Administration at Shenyang Pharmaceutical University, and Bachelor’s and Master’s degrees in Pharmacy from Shandong Medical University.